Company Overview and News

29
Getting Into The Weeds

2018-10-15 seekingalpha - 1
The changes that are underway closely mirror the process that alcohol went through after prohibition ended in the 1920s: liquor regained social acceptance and the product proliferated.
STZ.B ACBFF ITYBF TLRY APH WEED RLLRF GWP SMG IMBBY SHOP RRL CRON SF SFN STZ CGC HEIA QBC MFC ACB 0945 JNJ CBD MFC APHQF SFB IMBBF CNNRF

5
In crackdown, US FDA seeks details on new electronic cigarettes

2018-10-13 moneycontrol
Faced with a proliferation of new electronic cigarettes and a sharp rise in teen vaping, the US Food and Drug Administration on October 12 sent letters to 21 electronic cigarette manufacturers seeking information to assess whether the products are being marketed illegally.
WFC WFCNP IMBBY RAI BATS 4162 ITYBF IMBBF

 
Market report: Tobacco shares prove a drag as US regulators mull nicotine cap

2018-10-13 telegraph.co.uk
Tobacco shares went up in smoke yesterday after US regulators reignited fears of a crackdown on nicotine levels in cigarettes to help smokers to stub out the habit.
IMBBY MNGPY BATS 4162 ITYBF MNGPF STMZF EMG MS IMBBF BDEV

5
In crackdown, US FDA seeks details on new electronic cigarettes

2018-10-12 channelnewsasia
Faced with a proliferation of new electronic cigarettes and a sharp rise in teen vaping, the U.S. Food and Drug Administration on Friday sent letters to 21 electronic cigarette manufacturers seeking information to assess whether the products are being marketed illegally.
WFC WFCNP IMBBY RAI BATS 4162 ITYBF IMBBF

 
UPDATE 1-European stocks claw back losses, but on track for worst week since Feb

2018-10-12 reuters
LONDON (Reuters) - European stocks staged a half-hearted recovery on Friday from a sharp selloff on world markets, after Asian shares also had a partial bounceback overnight.
IMBBY BATS 4162 ITYBF IMBBF

 
E-cigarette maker Juul files complaints against "copycat products"

2018-10-04 channelnewsasia
LONDON: Juul Labs, the e-cigarette maker at the heart of a U.S. crackdown on youth vaping, has filed patent infringement complaints in the United States and Europe against what it said were copycat rivals.
IMBBY BATS 4162 ITYBF IMBBF

 
E-cigarette maker Juul files complaints against 'copycat products'

2018-10-04 channelnewsasia
LONDON: Juul Labs, the e-cigarette maker at the heart of a U.S. crackdown on youth vaping, has filed patent infringement complaints in the United States and Europe against what it said were copycat rivals.
IMBBY BATS 4162 ITYBF IMBBF

 
E-cigarette maker Juul files complaints against 'copycat products'

2018-10-04 reuters
LONDON (Reuters) - Juul Labs, the e-cigarette maker at the heart of a U.S. crackdown on youth vaping, has filed patent infringement complaints in the United States and Europe against what it said were copycat rivals.
IMBBY BATS 4162 ITYBF IMBBF

4
UPDATE 2-U.S. FDA seizes documents from Juul in latest e-cigarette crackdown

2018-10-02 reuters
(Reuters) - The U.S. Food and Drug Administration said on Tuesday it seized more than a thousand pages of documents from Juul Labs related to the company’s sales and marketing practices after a surprise inspection, the latest clamp down on e-cigarette companies.
WFC WFCNP IMBBY BATS 4162 ITYBF IMBBF

9
Big tobacco's new strategy: street sales

2018-10-01 nzherald.co.nz
Philip Morris International is taking a rather old-world approach to tackle slowing sales of its high-tech smoking devices in Japan: hitting the streets.
IMBBY PM JAPAF JAPAY 2914 BATS 4162 ITYBF IMBBF

8
Opinion | Has the Marlboro Man gasped his last

2018-09-27 livemint
Philip Morris International Inc., the maker of Marlboro cigarettes, has cut its full-year profit forecast because of the impact of the currency crises in Argentina and Turkey.
IMBBY PM BATS 4162 ITYBF IMBBF

10
My Favorite Tobacco Stock Is Now Undervalued By 50%

2018-09-25 seekingalpha
Altria offers investors a compelling FCF yield, sustainable dividend growth and an undervaluation of 50%, computed by my DCF.
IMBBY PM BUD ABI BATS 4162 ITYBF IMBBF

1
Imperial Brands looks to profit from vaping by next year

2018-09-25 telegraph.co.uk - 1
Imperial Brands, the tobacco giant behind Lambert & Butler, has linked staff bonuses to selling more vaping devices, as it hopes to make a profit from so-called "next generation products" (NGPs) by next year.
IMBBY ITYBF IMBBF

 
Imperial to launch new e-cigarette alongside heated tobacco

2018-09-25 channelnewsasia
LONDON: British tobacco company Imperial Brands aims to launch Nixx, a tobacco-infused e-cigarette, during the first part of 2019, its chief executive said on Tuesday, as the company bolsters its portfolio of cigarette alternatives.
IMBBY ITYBF IMBBF

 
European markets: Oil stocks hit highest since mid-July

2018-09-25 thehindubusinessline
European shares were supported in morning trading on Tuesday by gains among oil stocks, while British clothing retailer Next rallied after raising its profit guidance.
IMBBY 505200 ECQRY BATS 4162 ITYBF EICHERMOT IMBBF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: G4721W102